You are here:
Dear Doctor Letter (Rote-Hand-Brief) on Zaltrap® (aflibercept): Risk of osteonecrosis of the jaw
2016.03.17
Active substance: aflibercept
The company Sanofi-Aventis Deutschland GmbH is circulating information that cases of osteonecrosis of the jaw have been reported in cancer patients treated with Zaltrap®.
Download DHPC/Information letter , Download_VeroeffentlichtAm_EN